tbuckley/cabot-search huggingface dataset:
Using Cumulative Load to Explain How Body Mass Index and Daily Walking Relate to Worsening Knee Cartilage Damage Over Two Years: The <scp>MOST</scp> Study
Authors: Dana Voinier, Tuhina Neogi, Joshua J. Stefanik, Ali Guermazi, Frank W. Roemer, Louise M. Thoma, Hiral Master, Michael C. Nevitt, Cora E. Lewis, James Torner, Daniel K. White
Journal: Arthritis & Rheumatology (2019)

Knee cartilage damage is often linked to mechanical overloading. However, cartilage requires mechanical load to remain healthy, suggesting that underloading may be detrimental. This study was undertaken to examine knee overloading and underloading by defining cumulative load as the joint effects of body mass index (BMI) and daily walking, and examine the relationship between cumulative load and worsening cartilage damage over 2 years.We used data from the Multicenter Osteoarthritis Study. Steps/day, measured by accelerometry, and BMI were calculated at the 60-month visit. Cartilage damage on magnetic resonance imaging was semiquantitatively scored using the Whole-Organ Magnetic Resonance Imaging Score (WORMS) at the 60-month and 84-month visits; worsening damage was defined as increased WORMS between visits. Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated using binomial regression, with adjustment for potential confounders.Our study included 964 participants, 62% of whom were female, with a mean ± SD age of 66.9 ± 7.5 years. Participants had a mean ± SD BMI of 29.7 ± 4.8 kg/m2 and walked a mean ± SD of 7,153 ± 2,591 steps/day. Participants who walked a moderate number of steps/day (6,000-7,900) or a high number of steps/day (>7,900) and had a high BMI (>31 kg/m2 ) had a greater risk of worsening medial tibiofemoral (TF) damage (RR 2.83 [95% CI 1.46-5.48] and RR 2.61 [95% CI 1.50-4.54], respectively) compared with those who walked similar steps/day and had a low BMI (18-27 kg/m2 ). Participants with a low number of steps/day (<6,000) and a low BMI had a greater risk of worsening medial TF and lateral patellofemoral (PF) damage (RR 2.03 [95% CI 1.06-3.92] and RR 2.28 [95% CI 1.06-4.85], respectively) compared with those who walked a high number of steps/day and had a low BMI. Effect estimates for other compartments of the knee did not reach statistical significance.This study provides preliminary evidence that both overloading and underloading may be detrimental to medial TF cartilage, and underloading may be detrimental to lateral PF cartilage.
Standard operating procedure for curation and clinical interpretation of variants in cancer
Authors: Arpad M. Danos, Kilannin Krysiak, Erica K. Barnell, Adam C. Coffman, Joshua F. McMichael, Susanna Kiwala, Nicholas C. Spies, Lana M. Sheta, Shahil P. Pema, Lynzey Kujan, Kaitlin A. Clark, Amber Z. Wollam, Shruti Rao, Deborah I. Ritter, Dmitriy Sonkin, Gordana Raca, Wan-Hsin Lin, Cameron J. Grisdale, Raymond H. Kim, Alex H. Wagner, Subha Madhavan, Malachi Griffith, Obi L. Griffith
Journal: Genome Medicine (2019)

Abstract Manually curated variant knowledgebases and their associated knowledge models are serving an increasingly important role in distributing and interpreting variants in cancer. These knowledgebases vary in their level of public accessibility, and the complexity of the models used to capture clinical knowledge. CIViC (Clinical Interpretation of Variants in Cancer - www.civicdb.org ) is a fully open, free-to-use cancer variant interpretation knowledgebase that incorporates highly detailed curation of evidence obtained from peer-reviewed publications and meeting abstracts, and currently holds over 6300 Evidence Items for over 2300 variants derived from over 400 genes. CIViC has seen increased adoption by, and also undertaken collaboration with, a wide range of users and organizations involved in research. To enhance CIViC’s clinical value, regular submission to the ClinVar database and pursuit of other regulatory approvals is necessary. For this reason, a formal peer reviewed curation guideline and discussion of the underlying principles of curation is needed. We present here the CIViC knowledge model, standard operating procedures (SOP) for variant curation, and detailed examples to support community-driven curation of cancer variants.
Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Authors: Ilaria Iacobucci, Manja Meggendorfer, Niroshan Nadarajah, Stanley Pounds, Lei Shi, Chunxu Qu, Constance Baer, Claudia Haferlach, Wolfgang Kern, Charles G. Mullighan, Torsten Haferlach
Journal: Blood (2019)
Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
Authors: Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Rodney J. Hicks, Besiat Birbirsa, Mathias Bressel, Juliana Di Iulio, David Alan Westerman, Stephen Lade, Rishu Agarwal, Mark A. Dawson, Sarah-Jane Dawson, Rachel Koldej, David Ritchie, John F. Seymour, Andrew W. Roberts, Constantine S. Tam
Journal: Blood (2019)
Correction to: A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
Authors: Jianyu Weng, Peilong Lai, Le Qin, Yunxin Lai, Zhiwu Jiang, Chenwei Luo, Xin Huang, Suijing Wu, Dan Shao, Chengxin Deng, Lisi Huang, Zesheng Lu, Maohua Zhou, Lingji Zeng, Dongmei Chen, Yulian Wang, Xiaomei Chen, Suxia Geng, Robert Weinkove, Zhaoyang Tang, Chang He, Peng Li, Xin Du
Journal: Journal of Hematology & Oncology (2019)

The original article [1] contains an error in authorship whereby author, Robert Weinkove's name is mistakenly inverted. The configuration noted in this Correction article should be considered instead along with author's updated affiliation.
New power versus old: to beat antivaccination campaigners we need to learn from them—an essay by Kathryn Perera, Henry Timms, and Jeremy Heimans
Authors: Kathryn Perera, Henry Timms, Jeremy Heimans
Journal: BMJ (2019)

Healthcare professionals have grown up in "old power" institutions, but only by understanding how "new power" works can we respond effectively to the antivaccination narratives spread on social media, surmise <b>Kathryn Perera</b>, <b>Henry Timms</b>, and <b>Jeremy Heimans</b>
Beyond metaphors and semantics: A framework for causal inference in neuroscience
Authors: Roberto A. Gulli
Journal: Behavioral and Brain Sciences (2019)

Abstract The long-enduring coding metaphor is deemed problematic because it imbues correlational evidence with causal power. In neuroscience, most research is correlational or conditionally correlational; this research, in aggregate, informs causal inference. Rather than prescribing semantics used in correlational studies, it would be useful for neuroscientists to focus on a constructive syntax to guide principled causal inference.
Recommended Vaccines Underused During Pregnancy
Authors: Bridget Kuehn
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application
Authors: Annamaria Gulla, Eugenio Morelli, Mehmet Kemal Samur, Teru Hideshima, Giada Bianchi, Mariateresa Fulciniti, Rao Prabhala, Srikanth Talluri, Yu-Tzu Tai, Dharminder Chauhan, Ruben D. Carrasco, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2019)
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031
Authors: Jessica A. Pollard, Todd A. Alonzo, Patrick A. Brown, Robert B. Gerbing, Elizabeth Fox, John Kim Choi, Brian T. Fisher, Betsy A Hirsch, Samir Kahwash, John E. Levine, Michael R. Loken, Susana C. Raimondi, Katherine Tarlock, Andrew C. Wood, Lillian Sung, Anders E. Kolb, Alan S Gamis, Soheil Meshinchi, Richard Aplenc
Journal: Blood (2019)
Palliative medical management of inoperable malignant bowel obstruction with “triple therapy”: Dexamethasone, octreotide, and metoclopramide at a comprehensive cancer center.
Authors: Winston Wey, Moeena Mian, Rebecca Calabrese, Eric Hansen, Michelle Walter, Chong Wang, Amy Allen Case
Journal: Journal of Clinical Oncology (2019)

125 Background: Malignant bowel obstruction (MBO) is a complication of advanced malignancy. For inoperable patients, symptoms are often treated using analgesics, anticholinergics, and anti-emetics. There are, however, few published guidelines or algorithms for the medical management of MBO. Therefore, the objective was to measure the effect of the combination of dexamethasone, octreotide, and metoclopramide (“triple therapy”) in patients with MBO, compared to patients who received none of the three medications (“no drug therapy”). Methods: A retrospective cohort study was done of patients with malignant bowel obstruction admitted between 1/1/2015 to 12/31/2018. The outcome measures were a patient having de-obstruction (defined as toleration of oral intake and resolution of nausea and vomiting), as well as time to de-obstruction. Results: Medical staff identified 34 patients who received triple therapy and 34 patients who received no drug therapy. Patients who received triple therapy were more likely to reach de-obstruction, compared to patients who had no drug therapy (OR: 9.02 [1.43, 56.99], p=0.0194), after adjusting for related covariates (i.e. length of stay and percutaneous endoscopic gastrostomy [PEG] placement). Patients who reached de-obstruction in the triple therapy arm, however, took longer to reach de-obstruction than those in the no drug therapy arm (5.4 days versus 3.4 days, p=0.045). Conclusions: Triple drug therapy with dexamethasone, octreotide, and metoclopramide leads to higher rates of de-obstruction in patients with inoperable MBO, compared to patients who received none of the three drugs, though time to de-obstruction is longer.
Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer
Authors: Hideharu Kimura, Tomoyuki Araya, Taro Yoneda, Hiroki Shirasaki, Koji Kurokawa, Tamami Sakai, Hayato Koba, Yuichi Tambo, Shingo Nishikawa, Takashi Sone, Kazuo Kasahara
Journal: Cancer Communications (2019)
Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Authors: M. Kanazu, M. Mori, T. Shiroyama, I. Nagatomo, S. Ihara, K. Komuta, H. Suzuki, T. Hirashima, M. Kimura, F. Imamura
Journal: Annals of Oncology (2019)
Abstract 12928: Transcriptomics of Lung Molecular Remodeling in Pulmonary Hypertension Due to Left Heart Disease: Benefits of Combined PBI-4050/Valsartan Therapy
Authors: Julie Hussin, Quang Nguyen, Mohamed Jalloul Nsaibia, Jean-Christophe Grenier, Axel Seguin, Jean-Claude Tardif, Yanfen Shi, Martin G Sirois, Brigitte Grouix, Lyne Gagnon, Jocelyn Dupuis
Journal: Circulation (2019)

Pulmonary hypertension (PH) associated with left heart disease, or group II PH, is the most prevalent type of PH. Although it carries worse outcomes mainly due to the development of right ventricul...
LTBK-08. TOCA 511 &amp; TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
Authors: Timothy Cloughesy, Kevin Petrecca, Tobias Walbert, Nicholas Butowski, Michael Salacz, James Perry, Denise Damek, Daniela Bota, Chetan Bettegowda, Jay-Jiguang Zhu, Fabio Iwamoto, Dimitris Placantonakis, Nina Martinez, J Bradley Elder, George Kaptain, David Cachia, Yaron Moshel, Steven Brem, David Picconi, Nam Tran, Do-Hyun Nam, Chul-Kee Park, Joseph Landolfi, David Tran, Rohan Ramakrishna, Karen Fink, Deborah Heros, Gelareh Zadeh, Garth Nicholas, Vivek Mehta, H Ian Robins, Clark Chen, Marshall Pitz, Jason Heth, Seema Nagpal, Michael Pearlman, Manmeet Ahluwalia, Nimish Mohile, Ryan Merrell, David Schiff, Reid Thompson, Raphael Davis, David Macdonald, Thian Kheoh, Fairooz Kabbinavar, Alexander Lossos, Michael Vogelbaum
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Toca 511 (vocimagene amiretrorepvec) is a cancer-selective, retroviral replicating vector encoding a codon optimized, heat stabilized cytosine deaminase that converts Toca FC (extended-release 5-fluorocytosine, 5-FC) into the anticancer agent 5-fluorouracil. Three Ph1 studies in patients with recurrent high grade glioma have demonstrated a tolerable safety profile and encouraging efficacy. METHODS Toca 5 is a multi-national, randomized, open-label Ph3 trial (NCT02414165) of Toca 511 &amp; Toca FC versus standard of care (SOC) options that comprises Investigator’s choice of single agent chemotherapy (lomustine, temozolomide) or bevacizumab in patients who have undergone resection for first or second recurrence of glioblastoma or anaplastic astrocytoma. 403 patients were randomized 1:1 to the Toca arm or the SOC arm and stratified by IDH1 status, KPS, and geographic region. Primary endpoint was overall survival (OS), and secondary endpoints were durable response rate, durable clinical benefit rate, duration of durable response, and 12-month survival rate. The study used group sequential design including 2 interim analyses and 1 final analysis, and the stratified log-rank test are used for the analysis. RESULTS 271 events were observed for this analysis. Median follow-up was 22.8 months, and the Toca arm missed the primary endpoint (OS) compared to the SOC arm (11.1 months median compared to 12.2 months, HR=1.06, p=0.6154). All secondary endpoints showed no meaningful difference between the arms of the trial. The safety, tolerability and adverse event profile of Toca 511 and Toca FC was as expected for this patient population, with low incidences of Grade 3–4 adverse events. Pre-planned subgroup analyses showed compelling OS improvement in patients with secondary recurrence, and favorable trends in IDH1 mutant and AA population. Detailed data will be presented at the time of the conference.
A comparison of treatment preferences, decision making, and psychosocial outcomes in advanced cancer patients with and without minor children: A matched cohort study.
Authors: Eliza Myung Park, Allison Mary Deal, Laura C. Hanson, Donald L. Rosenstein, Laura J. Quillen, Claire E. Hailey, Stephanie A. Chien, Hanna Kelly Sanoff, Lisa A. Carey, Mi-Kyung Song
Journal: Journal of Clinical Oncology (2019)

91 Background: Patients with advanced cancer who have minor children face unique challenges when coping with their life-limiting illness and the impact of their illness on their families. The goal of this study was to examine whether psychosocial functioning, treatment preferences, and treatment decisions in advanced cancer differ by parental status. Methods: A cohort of 60 parents with metastatic solid tumors age-matched with 60 non-parents (N = 120) participated in three structured interviews assessing treatment preferences and decisions over six months with complementary medical record review. Participants also completed validated measures of psychosocial functioning. Results: Seventy percent (n = 85) of the sample completed all study assessments. Mean age (45 years, SD 8), mean performance status score (ECOG = 1.2, SD 0.9), median duration of metastatic illness (19 months, range 1-115), gender ratio (66% female), and dropout rates were similar between groups. Parents and non-parents reported similar overall health-related quality of life, but parents were more likely to report poorer emotional well-being (p = 0.006) and more symptoms of depression (p = 0.04) and anxiety (p = 0.04) than non-parents. Parents and non-parents were equally likely to describe life-extension as their primary goal of anti-neoplastic treatment. Parents reported greater willingness to live in pain (48% “very willing” vs 27%, p = 0.007) and accept intubation/ventilation (40% vs 20%, p = 0.01) for life-extension. Compared to non-parents, parents were more likely to report their family members as the most influential factor in their decision-making (44% vs 12%) and less likely to cite their oncologist’s recommendation (25% vs 41%). There were no significant differences between groups for completion of a health care power of attorney or living will. Conclusions: Compared to similarly aged adults with metastatic cancer, parents experience greater psychological distress, are more willing to live in pain for life extension, and place greater importance on family-related factors in their cancer treatment decision-making.
Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
Authors: Adam S. Kittai, Max J. Gordon, Agrima Mian, Lindsey Fitzgerald, Jennifer Bishop, Deborah M. Stephens, Sarah J. Nagle, Brian T. Hill, Alexey Danilov
Journal: Blood (2019)
Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration
Authors: Giang N. Nguyen, John K. Everett, Hayley Raymond, Samita Kafle, Elizabeth P. Merricks, Haig H. Kazazian, Timothy C. Nichols, Frederic D. Bushman, Denise E. Sabatino
Journal: Blood (2019)
Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists
Authors: F.I.L. Ting, J.M. Callueng, J. Vallente, R.A. Hurtado, A. Ramirez, L.I. Catedral, R.E. King, K.A. Mondragon, R. Velasco, J. Ignacio, C. Ngelangel
Journal: Annals of Oncology (2019)
The Future of Dementia Biomarkers Needs Better Neuropsychology
Authors: Sharon Naparstek, Omer Linkovski, Ruth O’Hara
Journal: American Journal of Psychiatry (2019)

In recent years, numerous models have been developed to predict the risk of dementia for individual persons (1, 2).Most of these models include sophisticated markers that are available only in specialized clinical care settings, such as during neuropsychological tests (1, 3).Although these tests yield additional value in predicting dementia, they are not readily available outside memory clinics, and even memory clinics face various issues, as mentioned by Naparstek and colleagues (3).In view of these shortcomings, we welcome the suggestions by Naparstek and colleagues in which they emphasize that the inclusion of computerized
Loneliness among cancer caregivers: The current state of the science.
Authors: Tamryn Gray, Desiree Rachel Azizoddin, Paula V. Nersesian
Journal: Journal of Clinical Oncology (2019)

19 Background: A cancer diagnosis can profoundly affect both patients and their caregivers. Providing care to a loved one with cancer places demands on caregivers that may result in changes to caregivers’ daily routines and disruptions to their social relationships, which may contribute to feelings of loneliness. Though caregivers’ psychosocial challenges have been extensively examined, loneliness—a determinant of health—has not been well-studied in this population. In this narrative review, we described the current state of the science related to loneliness among cancer caregivers, methods to assess loneliness, and recommended strategies to mitigate loneliness in cancer caregivers. Methods: We used evidence from peer-reviewed articles listed in PubMed, PsycINFO, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases. Articles were reviewed for the following inclusion criteria: (1) published in English, (2) caregivers of cancer patients, (3) loneliness as a study variable, and (4) peer-reviewed with no restriction on timeframe of publication. Caregivers were defined as relatives, friends, or partners who provide most of the care for someone with cancer. Results: Eighteen studies met inclusion criteria and were included in the analysis. Caregivers’ experiences of loneliness can contribute to negative effects on a caregiver’s social, emotional, and physical well-being. Social support interventions may not be sufficient to address this problem. Existing recommendations to help address loneliness include cognitive and psychological reframing, one-on-one and group therapy, befriending, resilience training, and technology-based interventions. Conclusions: As a condition of growing importance, loneliness can lead to poor outcomes in social, emotional, and physical health when left unaddressed. Limited understanding regarding loneliness in cancer caregivers poses a two-fold problem that has the potential to impact patient and caregiver outcomes. Future efforts should include intervention development to address loneliness as a determinant of health in this unique population, especially given the pivotal role of caregivers in providing care and impacting health outcomes for people with cancer.
Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes
Authors: Rafael Bejar
Journal: Journal of the National Comprehensive Cancer Network (2019)

Often unrecognized and underdiagnosed, myelodysplastic syndromes (MDS) are a rare group of cancers in which the bone marrow fails to produce sufficient healthy blood cells. Although patients with lower-risk MDS can live for >5 years, those with high-risk disease that evolves into acute myeloid leukemia is associated with significantly lower overall survival. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Rafael Bejar summarized current standard treatment options for patients with MDS and discussed the importance of genetic testing to identify mutations that may impact treatment. Finally, Dr. Bejar described emerging personalized treatment strategies for the management of this disease.